Prodomain of the proprotein convertase subtilisin/kexin Furin (ppFurin) protects from tumor progression and metastasis

被引:22
|
作者
Scamuffa, Nathalie [1 ,2 ]
Sfaxi, Fatma [1 ,2 ]
Ma, Jia [1 ,2 ]
Lalou, Claude [1 ,2 ]
Seidah, Nabil [3 ]
Calvo, Fabien [4 ]
Khatib, Abdel-Majid [1 ,2 ]
机构
[1] Univ Bordeaux 1, Angiogenesis Lab, F-33405 Talence, France
[2] INSERM, UMR 1029, F-33400 Talence, France
[3] Univ Montreal, Clin Res Inst Montreal IRCM, Lab Biochem Neuroendocrinol, Montreal, PQ, Canada
[4] Univ Paris 07, INSERM, UMRS 940, Inst Genet Mol, Paris, France
关键词
CELLS MALIGNANT PHENOTYPES; COLON-CARCINOMA CELLS; CANCER; GROWTH; INHIBITION; RECEPTOR; TUMORIGENICITY; INVASIVENESS; PROSEGMENTS; REPRESSES;
D O I
10.1093/carcin/bgt345
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Proteolytic maturation of various precursor proteins by the proprotein convertase Furin is now considered as a crucial step in tumor progression and metastasis. Here, we report the repression of the malignant and metastatic potential of carcinoma cells by the prodomain region of Furin (ppFurin), a naturally occurring inhibitor of this convertase. Overexpression of ppFurin in carcinoma cells in a stable manner significantly reduced their convertase activity and ability to mediate processing of the Furin cancer-related substrates platelet-derived growth factor (PDGF)-A and insulin-like growth factor-I receptor precursors. Unprocessed platelet-derived growth factor-A produced by ppFurin expressing cells failed to induce the activation of Akt in the platelet-derived growth factor receptor-expressing cells NIH BALB/c-3T3 and treatment of ppFurin expressing cells with insulin-like growth factor-I failed to induce Akt phosphorylation, compared with controls. The malignant potential of ppFurin expressing cells was significantly reduced as revealed by the loss of anchorage-independent growth and survival that associated their increased chemosensitivity. In vivo, comparative studies revealed that expression of ppFurin in the carcinoma cells MDA-MB-231 and CT-26 cells inhibited tumor growth when subcutaneously inoculated in nude mice. The use of an experimental liver colorectal metastasis model revealed the reduced ability of metastatic carcinoma CT-26 cells to colonize the liver in response to intrasplenic/portal inoculation. Further analyses revealed reduced Furin activity in tumors derived from intrasplenic inoculated mice with ppFurin expressing CT-26 cells. This finding highlights the role of Furin in the malignant and metastatic potential of tumor cells and suggests the possible consideration of using its naturally occurring inhibitor ppFurin in anticancer therapy.
引用
收藏
页码:528 / 536
页数:9
相关论文
共 50 条
  • [21] Targeting proprotein convertase subtilisin/kexin type 9 in mice and monkeys
    Wang, Ya
    Ma, Murong
    Wang, Jian-An
    Daugherty, Alan
    Lu, Hong S.
    CURRENT OPINION IN LIPIDOLOGY, 2019, 30 (02) : 154 - 155
  • [22] Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
    Shapiro, Michael D.
    Miles, Joshua
    Tavori, Hagai
    Fazio, Sergio
    ANNALS OF INTERNAL MEDICINE, 2018, 168 (05) : 376 - 379
  • [23] Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics
    Stein, Evan A.
    Swergold, Gary D.
    CURRENT ATHEROSCLEROSIS REPORTS, 2013, 15 (03)
  • [24] The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis
    Mousavi, S. A.
    Berge, K. E.
    Leren, T. P.
    JOURNAL OF INTERNAL MEDICINE, 2009, 266 (06) : 507 - 519
  • [25] Proprotein Convertase Subtilisin/Kexin 6 Is Involved In Lipid Metabolism In Liver
    Suur, Bianca
    Chemaly, Melody
    Karadimou, Glykeria
    Jin, Hong
    Kronqvist, Malin
    Lengquist, Mariette
    van der Laan, Sander W.
    Lleal, Maria Sabater
    Malarstig, Anders
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2022, 42
  • [26] Proprotein convertase subtilisin/kexin type 4 in mammalian fertility: a review
    Gyamera-Acheampong, Charles
    Mbikay, Majambu
    HUMAN REPRODUCTION UPDATE, 2009, 15 (02) : 237 - 247
  • [27] Proprotein convertase subtilisin/kexin type 9 inhibition as the next statin?
    Rakipovski, Gunaj
    Hovingh, G. Kees
    Nyberg, Michael
    CURRENT OPINION IN LIPIDOLOGY, 2020, 31 (06) : 340 - 346
  • [28] Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review
    Wu, Na-Qiong
    Shi, Hui-Wei
    Li, Jian-Jun
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [29] Inhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia
    Ascaso, Juan F.
    ENDOCRINOLOGIA Y NUTRICION, 2016, 63 (06): : 255 - 257
  • [30] Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
    Filippatos, Theodosios D.
    Christopoulou, Eliza C.
    Elisaf, Moses S.
    CURRENT OPINION IN LIPIDOLOGY, 2018, 29 (04) : 333 - 339